A Sanofi experimental drug showed promise in treating asthma, supporting the French drugmaker’s plan to begin more late-stage studies of a medicine that it sees as a potential blockbuster.
The therapy, called rilzabrutinib, helped adults better control their asthma and alleviated symptoms in a mid-stage study, Sanofi said in a statement Wednesday. The results were positive for groups that received both a high dose and a low dose of the oral treatment during a 12-week study, with improvements seen as soon as the second week, Sanofi said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.